Professor Tim Underwood takes us through the history of oesophageal cancer, where we are now, and some of the science that is done to ask questions about where we might go with the treatment of oesophageal cancer.

Dr John Findlay (Oxford University) presents 'Heavy Petting in Oesophago-gastric Cancer’ and Mr Nick Maynard (Oxford University) presents ‘How Much Should we Tell the Public About Outcomes from Oesophagectomy?’

Ms Jennifer Whitfield talks about the 100,000 Genomes Project, which aims to establish a new genomic medicine service through the NHS by sequencing the entire genomes of around 70,000 people with rare inherited diseases or cancer.

Transcription is a tightly regulated process, where chemical modifications initiate the duplication of genetic material. This epigenetic process is often dysregulated in cancer, but it can be targeted with small molecule inhibitors.

Transcription is a tightly regulated process, where chemical modifications initiate the duplication of genetic material. This epigenetic process is often dysregulated in cancer, but it can be targeted with small molecule inhibitors.

Identifying genes that increase the risk of bowel or other cancers allows us to offer preventative measures, such as removing tumours at an early stage. A better understanding of how and why cancers grow also helps develop improved treatments.

Cancer research now generates huge amounts of data, and sophisticated computational tools are needed to answer biological questions. Making sense of this variability at molecular level will help us better tailor treatments to individual cancer patients.

Identifying genes that increase the risk of bowel or other cancers allows us to offer preventative measures, such as removing tumours at an early stage. A better understanding of how and why cancers grow also helps develop improved treatments.

Cancer research now generates huge amounts of data, and sophisticated computational tools are needed to answer biological questions. Making sense of this variability at molecular level will help us better tailor treatments to individual cancer patients.

A film produced as part of the Oxford Open Doors 2014, reflecting on some of the exciting cancer research being undertaken in the Oxford Chemistry Department. With Professor Chris Schofield, Oxford University, and Charlotte Richards, Cancer Research UK.

Dr Sonia Trigueros explains how she is using nanotechnologies to create targeted drug delivery systems. Chemotherapy is a particularly harmful treatment, with patients losing their hair and suffering from infections due to damage to their immune systems.

To truly understand disease, we need to understand the underlying chemical processes that direct human biology. Dr Emily Flashman introduces some of the research in the Department of Chemistry that will help improve our health in future.

In this Health, Environment and Development seminar, Peter Scarborough (a UL in Public Health) discusses the impact of achieving environmental sustainable diets on deaths from cardiovascular disease and cancer in the UK. 18 October 2011.

This Oxford at Said seminar was dedicated to cancer research. Three researchers from the University of Oxford give insights into recent advances in the field of cancer cell biology, therapy and epidemiology.

Conrad Keating, biographer of Richard Doll, lectures on the life of the cancer epidemiologist and lifelong socialist who contributed much to our understanding of the effects of smoking and changed the way we regard smoking and public health.

In this podcast, Alan Milburn, MP for Darlington and former Secretary of State for Health, explains the importance of international support to help improve cancer care in Africa, and talks about the challenges that must to be overcome.

Professor David Kerr discusses his work on colorectal cancer, the process of how new treatments are developed, the changes in the NHS that he has witnessed over his career, and how cancer care differs in developing countries.